Invesco Ltd. Makes New Investment in NewAmsterdam Pharma (NASDAQ:NAMS)

Invesco Ltd. bought a new stake in NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 150,559 shares of the company's stock, valued at approximately $3,869,000. Invesco Ltd. owned approximately 0.16% of NewAmsterdam Pharma at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. National Bank of Canada FI bought a new position in shares of NewAmsterdam Pharma during the 4th quarter valued at about $51,000. Mirae Asset Global Investments Co. Ltd. purchased a new stake in NewAmsterdam Pharma in the fourth quarter worth approximately $80,000. Barclays PLC grew its position in NewAmsterdam Pharma by 1,813.4% during the third quarter. Barclays PLC now owns 7,596 shares of the company's stock valued at $126,000 after acquiring an additional 7,199 shares during the last quarter. KLP Kapitalforvaltning AS purchased a new position in shares of NewAmsterdam Pharma during the fourth quarter worth approximately $154,000. Finally, HB Wealth Management LLC bought a new stake in shares of NewAmsterdam Pharma in the 4th quarter worth approximately $224,000. 89.89% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other NewAmsterdam Pharma news, Director James N. Topper acquired 4,005 shares of the company's stock in a transaction that occurred on Tuesday, March 4th. The shares were bought at an average price of $21.02 per share, with a total value of $84,185.10. Following the completion of the acquisition, the director now owns 3,012,434 shares in the company, valued at $63,321,362.68. This represents a 0.13 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO Louise Frederika Kooij sold 150,000 shares of the business's stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $20.37, for a total transaction of $3,055,500.00. Following the sale, the chief accounting officer now owns 15,000 shares of the company's stock, valued at $305,550. This trade represents a 90.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 19.50% of the stock is currently owned by corporate insiders.

NewAmsterdam Pharma Stock Performance

Shares of NAMS traded up $0.20 on Friday, hitting $20.23. 104,341 shares of the stock traded hands, compared to its average volume of 597,585. The company has a market capitalization of $2.22 billion, a PE ratio of -7.78 and a beta of -0.01. NewAmsterdam Pharma has a one year low of $14.06 and a one year high of $27.29. The business has a 50 day simple moving average of $19.63 and a 200 day simple moving average of $21.21.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last posted its earnings results on Wednesday, February 26th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.47). The business had revenue of $12.77 million for the quarter, compared to analyst estimates of $3.30 million. On average, equities analysts expect that NewAmsterdam Pharma will post -1.75 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the company. Royal Bank of Canada reissued an "outperform" rating and issued a $40.00 target price on shares of NewAmsterdam Pharma in a research note on Friday, January 24th. Needham & Company LLC reissued a "buy" rating and set a $42.00 price objective on shares of NewAmsterdam Pharma in a research note on Tuesday, April 8th. HC Wainwright reaffirmed a "buy" rating and issued a $48.00 target price on shares of NewAmsterdam Pharma in a research note on Tuesday, January 14th. Scotiabank increased their price target on shares of NewAmsterdam Pharma from $47.00 to $52.00 and gave the company a "sector outperform" rating in a research report on Thursday, February 27th. Finally, UBS Group set a $41.00 price objective on shares of NewAmsterdam Pharma in a research report on Monday, March 3rd. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus target price of $43.33.

NewAmsterdam Pharma Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.